U.S. regulatory status

Semax

Also known as Semax acetate

In limboPCAC recommended listing (8-5, Jul 24, 2026) - advisory only; still not on the 503A list

Is Semax legal right now?

Semax is a synthetic heptapeptide with no FDA-approved drug product and no USP monograph in the United States, so a positive listing on the 503A (or 503B) bulk drug substances list is the only route to legal compounding - and Semax is on neither. On July 24, 2026 the FDA's Pharmacy Compounding Advisory Committee voted 8-5, with 1 abstention, to recommend adding it to the 503A list, against the recommendation of the FDA's own review staff. The vote is advisory and does not bind the FDA. Nothing about Semax's legal status changed on the day of the vote. Before it could be compounded lawfully the FDA would have to accept the recommendation and complete notice-and-comment rulemaking - a process the agency has not begun and that is generally estimated at 12 to 24 months.

In limbo: Nominated or removed from a restricted list but NOT approved - the headline implies a change, but the legal reality did not move.

Verified Aug 11, 2026 (ET) · status held since Jul 24, 2026

Primary source: Federal Register All 7 sources

The committee vote

July 24, 2026 ET

Question put to the FDA Pharmacy Compounding Advisory Committee (PCAC)“Should Semax (free base) be placed on the list? - and, as a separate vote, Semax acetate?”

Recommended by the committee

8 in favour
5 against
1 abstained

14 votes recorded. Tally reported by Healio and the FDA Law Blog (Hyman, Phelps & McNamara). The panel was not the same size for every substance - the meeting roster seats temporary voting members for single topics - so the totals legitimately differ between votes - the FDA has not yet published the meeting minutes, so treat the counts as reported rather than official.

What this does not do: an advisory committee recommendation is not an FDA decision and does not bind the agency. Semax is not on the 503A Bulk Drug Substances List, and a pharmacy compounding it today has no more federal authorisation than it did the day before the vote. Only a completed FDA rulemaking can change that.

Where it sits in the process

Nominated (completed)
Under review (advisory committee recommended it - not yet legal)
Rulemaking (upcoming)
Compounding-legal (upcoming)

Recommended by the advisory committee - and still not legal to compound. The vote is advisory and does not bind the FDA. Nothing changes until the FDA accepts the recommendation and completes notice-and-comment rulemaking. This is real forward motion, not a green light.

What changed last

Jul 24, 2026
FDA advisory committee (PCAC) voted 8-5, with 1 abstention, to recommend adding Semax to the 503A list. Advisory only - Semax is still not on the list and still not legal to compound until the FDA accepts the recommendation and completes rulemaking.
Not legalizedView on healio.com
Apr 16, 2026
Placed on the July 24, 2026 FDA advisory committee agenda for possible inclusion on the 503A list.
Review scheduledView on federalregister.gov

Status elsewhere

Semax: regulatory status by jurisdiction
Jurisdiction	Status	Note
United States (FDA)	In limbo	Not on the 503A Bulks List. PCAC recommended adding it on Jul 24, 2026 (8-5, 1 abstention); the recommendation is advisory and the FDA has not acted.
Australia (TGA)	Unscheduled	Not individually named in the Poisons Standard; sits in a grey area.
Sport / anti-doping (WADA)	Restricted	Not individually named, but prohibited at all times under the S0 catch-all for non-approved substances.

Sources & transparency

Sources for this entry

Federal Register - PCAC notice of meeting (Docket FDA-2025-N-6895) Federal Register · primarySemax (free base and acetate) on the July 24, 2026 agenda.
FDA - PCAC meeting page, July 23-24, 2026 FDA · primaryOfficial meeting record. FDA has not yet published the minutes or vote tallies.
FDA - PCAC July 23-24, 2026: questions put to the committee FDA · primaryFDA's own vote questions. Confirms each substance was voted on twice - free base and acetate separately - and gives the session order.
FDA - PCAC July 23-24, 2026: meeting roster FDA · primaryVoting members plus temporary voting members seated for single topics, which is why the vote totals differ between substances.
FDA Law Blog - FDA's Pep(tide) Rally (Hyman, Phelps & McNamara) analysisSemax moved to Category 2 in 2023; under PCAC review; recommendation non-binding.
Healio - FDA committee recommends looser restrictions for several peptides analysisReported per-substance vote tallies; also records that FDA review staff recommended against all seven.
Mintz - FDA's Advisory Committee Votes on Peptides: What It Does and Doesn't Do analysisLegal analysis: the vote is not an agency action and nothing has legally changed.

Last verified by a human: Aug 11, 2026 (ET) · how we verify
Who runs this: Peptlas Research Team - independent. About us.
What we sell: Nothing. No products, no affiliates, no sponsored placements.

This page reports publicly available regulatory status for information only. It is not medical or legal advice and makes no health claim. See our full disclaimer.